NeuroMetrix (NASDAQ:NURO) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of NeuroMetrix (NASDAQ:NURO) in a report issued on Monday morning. The firm issued a sell rating on the medical device company’s stock.

NeuroMetrix Price Performance

NASDAQ:NURO opened at $4.42 on Monday. The firm has a 50-day moving average of $4.15 and a 200-day moving average of $4.02. The company has a market cap of $9.06 million, a PE ratio of -0.96 and a beta of 2.18. NeuroMetrix has a one year low of $2.66 and a one year high of $4.73.

Hedge Funds Weigh In On NeuroMetrix

A hedge fund recently bought a new stake in NeuroMetrix stock. Renaissance Technologies LLC acquired a new position in NeuroMetrix, Inc. (NASDAQ:NURO) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 11,560 shares of the medical device company’s stock, valued at approximately $46,000. Renaissance Technologies LLC owned about 0.57% of NeuroMetrix at the end of the most recent quarter. Institutional investors own 19.40% of the company’s stock.

About NeuroMetrix

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.